Compound ID | 163
Class: Oxazolidinone
Spectrum of activity: | Gram-positive |
Details of activity: | Gram-positive infections including MRSA. |
Institute where first reported: | MicuRx Pharmaceuticals, USA |
Year first mentioned: | 2015 |
Highest developmental phase: | Preclinical |
Development status: | Active |
External links: | |
Citation: |